Report on the program of the use of convalescent plasma in the treatment of patients with COVID-19 in the Czech Republic and the results of the national multicentre study RESCOVID-19
Authors:
M. Bohoněk 1,2; D. Řezáč 3,4; D. Kutáč 1,5; P. Vabroušek 1; J. Kubů 1,6; T. Jakub 1; K. Trojanová 1; M. Urbánková 1; A.- Chrdle 7 9; K. Volfová 7; J. Sagan 10,11; Š. Blahutová 12; J. Máca 13,14; I. Rychlík 15; K. Vonášková 15; R. Majerčin 16; R. Kralova 16; P. Štěpánek 17; M. Holub 3
Authors‘ workplace:
Oddělení hematologie a krevní transfuze, ÚVN – VFN, Praha
1; Fakulta biomedicínského inženýrství, ČVÚT, Praha
2; Klinika infekčních nemocí 1. LF UK a ÚVN – VFN, Praha
3; Agentura vojenského zdravotnictví, Ministerstvo obrany ČR
4; Katedra vojenského vnitřního lékařství a vojenské hygieny, Fakulta vojenského zdravotnictví, Univerzita obrany Brno, Hradec Králové
5; Fakultní nemocnice Bulovka, Praha
6; Infekční oddělení, Nemocnice České Budějovice
7; Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, United Kingdom
8; Fakulta zdravotních a sociálních věd, Jihočeská univerzita, České Budějovice
9; Klinika infekčního lékařství LF OU a FN Ostrava
10; Oddělení klinických studií, FN Ostrava
11; Ústav laboratorní medicíny, LF Ostrava
12; Klinika anesteziologie resuscitace a intenzivní medicíny FN Ostrava
13; Ústav fyziologie a patologické fyziologie, LF Ostrava
14; Interní klinika 3. LF UK a FN Královské Vinohrady, Praha
15; Oddělení anesteziologie a resuscitace, Oblastní nemocnice Jičín
16; Oddělení anesteziologie a resuscitace, Oblastní nemocnice Náchod
17
Published in:
Transfuze Hematol. dnes,29, 2023, No. 3, p. 193-199.
Category:
Original Papers
doi:
https://doi.org/10.48095/cctahd2023prolekare.cz15
Overview
Introduction: The production and use of convalescent plasma (CP) collected from persons after COVID-19 disease became a rapidly available treatment modality in a number of countries, including the Czech Republic, during the SARS-CoV-2 pandemic. Between April 2020 and April 2021, a total of 19,079 CP units were produced in the Czech Republic, of which 14,197 units were dispensed to approximately 7,100 patients in 61 hospitals. Of the total number of 131,000 hospitalized patients with COVID-19 during the given period, CP was administered to 5.4%. The retrospective multicentre RESCOVID-19 study was conducted to evaluate the eff ectiveness and safety of CP treatment of COVID-19 disease. Material and methods: The primary objective of the study, which involved 6 hospitals, was to evaluate the clinical eff ectiveness of CP in the treatment of COVID-19 compared to standard therapy without the administration of CP. The secondary objective was to evaluate the impact of the level of anti-SARS-CoV-2 antibodies in CP on survival and speed of recovery. The incidence and severity of adverse reactions associated with the administration of CP were also determined. Results: A total of 1,506 patients were enrolled in the study, of which 414 (27.3%) were treated with CP and 1092 (72.7%) were without this treatment (control group). The results of the logistic regression model showed a mean survival probability estimate of 91.8% for patients in the CP group administered within 3 days of symptom onset (N = 100), which is similar to the control group with a survival probability of 91.7%. The worst results were found in the group of patients with CP administered after the 3rd day (N = 313) where survival was only 82.3%. However, patients with CP transfused by the 3rd day recovered signifi cantly earlier compared to controls and patients with CP transfused after the 3rd day. The study did not demonstrate an eff ect of the amount of anti-SARS-CoV-2 antibodies in the CP on survival (78% survival with VNP ≤ 320, 78% survival with VNP ≥ 320). Adverse eff ects related to CP administration were recorded in 2.17% of patients; clinically mild in all cases. Conclusion: The results of the study showed that early application of CP accelerated recovery but had no eff ect on COVID-19 survival. The anti-SARS-CoV-2 antibody concentration in CP had no eff ect on survival and speed of recovery.
Keywords:
COVID-19 – convalescent plasma – therapeutic result – virus-neutralized antibodies
Sources
1. Woo PCY, Lau SK, Wong BH, et al. Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin and Diag Lab Imunol. 2004; 11: 665–668.
2. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24: 44–46.
3. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56: 919–922.
4. Zhang JS, Chen JT, Liu YX, et al. A serological survey on neutralizing antibody titer of SARS convalescent sera. J Med Virol. 2005; 77: 147–150.
5. Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016; 22: 1554–1561.
6. Mair-Jenkins J, Saavedra-Campos M, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015; 211: 80–90.
7. Garraud O, Heshmati F, Pozzetto B, et al. Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow. Transfus Clin Biol. 2016; 23: 39–44.
8. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004; 2: 695–703.
9. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145: 599–609.
10. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52: 447–456.
11. World Health Organisation. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks, WHO Interim Guidance for National Health Authorities and Blood Transfusion Services, Version 1.0, September 2014, WHO/HIS/SDS/2014.8. Available from: https: //apps.who.int/iris/handle/10665/135591.
12. Sahr F, Ansumana R, Massaquoi TA, et al. Evaluation of convalescent whole blood for treating Ebola virus disease in Freetown, Sierra Leone. J Infect. 2017; 74: 302–309.
13. Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. Preprint. medRxiv. 2020; 2020.08.12.20169359.
14. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021; 384: 610-618.
15. European Commision. An EU Programme of COVID-19 convalescent plasma collection and transfusion. Available from: https: //ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf.
16. Simonovich VA, Burgos Pratx LD, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med 2021; 384: 619–623.
17. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P on behalf of PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre rendomised controlled trial (PLACID Trial). BMJ 2020; 371: m3939.
18. RECOVERY Collaborattive Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet 2021; 397: 2049–2059.
19. Bohoněk M, Řezáč D, Holub M. Výroba a použití rekonvalescentní plazmy pro léčbu COVID-19 s přihlédnutím ke zkušenostem v ÚVN Praha, Čas Lék Čes. 2020; 159: 175–180.
20. Černý V, Bohoněk M, Dlouhý P, Vašáková M. Mezioborové stanovisko k podávání rekonvalescentní plazmy u pacientů s COVID-19, ev. č. ČSARIM: 18/2021, 2.3.2021.
21. Bohoněk M. Výroba a použití rekonvalescentní plazmy anti-SARS-CoV-2 v ČR: stručná informace Transfuze Hematol Dnes. 2021; 27 (2): 189–190.
22. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020; 383: 1813–1826.
23. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005; 173: 489–495.
24. Státní ústav pro kontrolu léčiv, Výroční zprávy k hemovigilanci – archiv. Dostupné z: https: //www.sukl.cz/vyrocni-zpravy-k-hemo- vigilanci-archiv.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2023 Issue 3
Most read in this issue
- Hereditary haemorrhagic teleangiectasia (Rendu-Osler-Weber disease)
- Boris Bubeník slaví sedmdesátiny
- Managing BTK inhibitor treatment-related adverse events in patients with chronic lymphocytic leukaemia – cardiovascular complications and bleeding
- Covid score – the contribution in prognostic stratification of patients with COVID-19